<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Platelet <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa (GPIIb/IIIa) receptors represent the final common pathway for aggregation </plain></SENT>
<SENT sid="1" pm="."><plain>GPIIb/IIIa inhibition with antibodies or RGD <z:chebi fb="7" ids="16670">peptides</z:chebi> prevents <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study examined the ability of SC-49992 (SC), a GPIIb/IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, to prevent <z:mp ids='MP_0005048'>thrombosis</z:mp> in a canine model of carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Both carotid arteries of anaesthetised dogs were instrumented with Doppler probes </plain></SENT>
<SENT sid="4" pm="."><plain>A 300 microA current was applied to the intimal surface of the right carotid artery via an intraluminal electrode; time to occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was noted </plain></SENT>
<SENT sid="5" pm="."><plain>SC (30 and 60 micrograms/.kg-1 x min-1, intravenously) or saline was infused for 240 min </plain></SENT>
<SENT sid="6" pm="."><plain>The procedure for <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was repeated after 60 min of drug infusion for the left carotid artery </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: SC did not alter heart rate or blood pressure </plain></SENT>
<SENT sid="8" pm="."><plain>Frequency of occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation was reduced or prevented in a dose dependent manner (control = 100%, n = 12; SC 30 micrograms = 50%, n = 6; SC 60 micrograms = 0%, n = 6; p &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>SC resulted in a reduction in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight (p &lt; 0.05) v control </plain></SENT>
<SENT sid="10" pm="."><plain>Ex vivo platelet aggregation to <z:chebi fb="13" ids="16761">ADP</z:chebi> and <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> was inhibited </plain></SENT>
<SENT sid="11" pm="."><plain>Platelet reactivity remained inhibited 60 min after cessation of SC infusion </plain></SENT>
<SENT sid="12" pm="."><plain>In a second group of animals, a carotid artery <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was formed and lysed with administration of anisoylated plasminogen streptokinase activator complex (0.05 U.kg-1) </plain></SENT>
<SENT sid="13" pm="."><plain>SC (60 micrograms.kg-1 x min-1, intravenously, n = 6) or saline (n = 6) was infused for 240 min </plain></SENT>
<SENT sid="14" pm="."><plain>In dogs receiving saline there was an 83% rate of rethrombosis; none of the SC treated animals had reocclusion after recanalisation (p &lt; 0.05) </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: SC-49992 inhibits ex vivo platelet aggregation, prevents occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in a canine model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, and prevents rethrombosis after thrombolysis </plain></SENT>
<SENT sid="16" pm="."><plain>The data are consistent with results obtained with murine monoclonal antibodies directed against the platelet GPIIb/IIIa receptor </plain></SENT>
</text></document>